GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » ROE %

SomaLogic (SomaLogic) ROE % : -17.52% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SomaLogic ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. SomaLogic's annualized net income for the quarter that ended in Sep. 2023 was $-88.63 Mil. SomaLogic's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $505.95 Mil. Therefore, SomaLogic's annualized ROE % for the quarter that ended in Sep. 2023 was -17.52%.

The historical rank and industry rank for SomaLogic's ROE % or its related term are showing as below:

SLGC' s ROE % Range Over the Past 10 Years
Min: -28.52   Med: -21.94   Max: -18.59
Current: -24.03

During the past 3 years, SomaLogic's highest ROE % was -18.59%. The lowest was -28.52%. And the median was -21.94%.

SLGC's ROE % is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 4.035 vs SLGC: -24.03

SomaLogic ROE % Historical Data

The historical data trend for SomaLogic's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomaLogic ROE % Chart

SomaLogic Annual Data
Trend Dec20 Dec21 Dec22
ROE %
-28.52 -21.94 -18.59

SomaLogic Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.78 -33.81 -24.92 -18.87 -17.52

Competitive Comparison of SomaLogic's ROE %

For the Health Information Services subindustry, SomaLogic's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SomaLogic's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SomaLogic's ROE % distribution charts can be found below:

* The bar in red indicates where SomaLogic's ROE % falls into.



SomaLogic ROE % Calculation

SomaLogic's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-109.157/( (612.024+562.558)/ 2 )
=-109.157/587.291
=-18.59 %

SomaLogic's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-88.628/( (515.152+496.739)/ 2 )
=-88.628/505.9455
=-17.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.


SomaLogic  (NAS:SLGC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-88.628/505.9455
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-88.628 / 88.192)*(88.192 / 575.397)*(575.397 / 505.9455)
=Net Margin %*Asset Turnover*Equity Multiplier
=-100.49 %*0.1533*1.1373
=ROA %*Equity Multiplier
=-15.41 %*1.1373
=-17.52 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-88.628/505.9455
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-88.628 / -86.716) * (-86.716 / -95.7) * (-95.7 / 88.192) * (88.192 / 575.397) * (575.397 / 505.9455)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.022 * 0.9061 * -108.51 % * 0.1533 * 1.1373
=-17.52 %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


SomaLogic ROE % Related Terms

Thank you for viewing the detailed overview of SomaLogic's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


SomaLogic (SomaLogic) Business Description

Traded in Other Exchanges
N/A
Address
2945 Wilderness Place, Boulder, CO, USA, 80301
SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.
Executives
Alison Marie Roelke officer: Chief People Officer 900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich officer: Interim CEO C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez officer: General Counsel 6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs director C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey director 8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson director C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman officer: Chief Financial Officer C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post director 998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis director 13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake director C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi director